Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Author Verified
RCT
ACE Report #6307
Ace Report Cover Tumour

The effect of adjuvant aromatase inhibitors on BMD in women with breast cancer


Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial

Lancet Oncol. 2014 Apr;15(4):474-82. doi: 10.1016/S1470-2045(14)70035-X. Epub 2014 Mar 11

Contributing Authors: PE Goss DL Hershman AM Cheung JN Ingle S Khosla V Stearns H Chalchal K Rowland HB Muss HM Linden J Scher KI Pritchard CR Elliott T Badovinac-Crnjevic J St Louis JA Chapman LE Shepherd

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

497 postmenopausal women with hormone-receptor-positive breast cancer were randomized to receive adjuvant exemestane 25 mg or anastrozole 1 mg daily for 5 years. Two subgroups were identified: those with baseline T-scores of -2.0 or greater at the spine and hip (subgroup 1), and those with baseline T-scores less than -2.0 at the spine and hip and taking bisphosphonates (subgroup 2). Results at 2 y...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.